Plain-English translation of NCT06902272 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is studying a special blood test that can detect tiny amounts of cancer DNA in your bloodstream. Researchers want to see if this blood test can help predict whether your lung cancer will respond well to treatment with chemotherapy and an immunotherapy drug called , and whether any cancer cells remain after your surgery. The study will also look at whether the medication can help prevent your cancer from coming back.
Currently, doctors don't have a reliable way to know early on if a patient's cancer will respond well to treatment or if cancer cells are still hiding after surgery. This trial exists to test whether a simple blood test could give doctors this important information so they can personalize treatment and catch any returning cancer earlier.
You likely qualify if…
You likely don't qualify if…
You would receive standard chemotherapy and immunotherapy before surgery to shrink your tumor, along with blood tests to monitor cancer DNA levels throughout your treatment. After your surgery to remove the tumor, you would continue taking the immunotherapy medication and have regular blood tests and imaging scans for monitoring. Your total involvement would last up to 2.5 years.
AI-generated summary from trial data · Aug 13, 2026 · Not medical advice
United States